Repurposing of drugs : An attractive pharmacological strategy for cancer therapeutics
Copyright © 2020 Elsevier Ltd. All rights reserved..
Human malignancies are one of the major health-related issues though out the world and anticipated to rise in the future. The development of novel drugs/agents requires a huge amount of cost and time that represents a major challenge for drug discovery. In the last three decades, the number of FDA approved drugs has dropped down and this led to increasing interest in drug reposition or repurposing. The present review focuses on recent concepts and therapeutic opportunities for the utilization of antidiabetics, antibiotics, antifungal, anti-inflammatory, antipsychotic, PDE inhibitors and estrogen receptor antagonist, Antabuse, antiparasitic and cardiovascular agents/drugs as an alternative approach against human malignancies. The repurposing of approved non-cancerous drugs is an effective strategy to develop new therapeutic options for the treatment of cancer patients at an affordable cost in clinics. In the current scenario, most of the countries throughout the globe are unable to meet the medical needs of cancer patients because of the high cost of the available cancerous drugs. Some of these drugs displayed potential anti-cancer activity in preclinic and clinical studies by regulating several key molecular mechanisms and oncogenic pathways in human malignancies. The emerging pieces of evidence indicate that repurposing of drugs is crucial to the faster and cheaper discovery of anti-cancerous drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Seminars in cancer biology - 68(2021) vom: 15. Jan., Seite 258-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kirtonia, Anuradha [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2022 Date Revised 28.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semcancer.2020.04.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309635128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309635128 | ||
| 003 | DE-627 | ||
| 005 | 20231225134341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semcancer.2020.04.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309635128 | ||
| 035 | |a (NLM)32380233 | ||
| 035 | |a (PII)S1044-579X(20)30094-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kirtonia, Anuradha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing of drugs |b An attractive pharmacological strategy for cancer therapeutics |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2022 | ||
| 500 | |a Date Revised 28.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Human malignancies are one of the major health-related issues though out the world and anticipated to rise in the future. The development of novel drugs/agents requires a huge amount of cost and time that represents a major challenge for drug discovery. In the last three decades, the number of FDA approved drugs has dropped down and this led to increasing interest in drug reposition or repurposing. The present review focuses on recent concepts and therapeutic opportunities for the utilization of antidiabetics, antibiotics, antifungal, anti-inflammatory, antipsychotic, PDE inhibitors and estrogen receptor antagonist, Antabuse, antiparasitic and cardiovascular agents/drugs as an alternative approach against human malignancies. The repurposing of approved non-cancerous drugs is an effective strategy to develop new therapeutic options for the treatment of cancer patients at an affordable cost in clinics. In the current scenario, most of the countries throughout the globe are unable to meet the medical needs of cancer patients because of the high cost of the available cancerous drugs. Some of these drugs displayed potential anti-cancer activity in preclinic and clinical studies by regulating several key molecular mechanisms and oncogenic pathways in human malignancies. The emerging pieces of evidence indicate that repurposing of drugs is crucial to the faster and cheaper discovery of anti-cancerous drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-inflammatory | |
| 650 | 4 | |a Antibiotic | |
| 650 | 4 | |a Antidiabetic | |
| 650 | 4 | |a Antifungal | |
| 650 | 4 | |a Antipsychotic | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Drug repurposing/repositioning | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a PDE inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Gala, Kavita |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Stina George |e verfasserin |4 aut | |
| 700 | 1 | |a Pandya, Gouri |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Amit Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Sethi, Gautam |e verfasserin |4 aut | |
| 700 | 1 | |a Khattar, Ekta |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Manoj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in cancer biology |d 1991 |g 68(2021) vom: 15. Jan., Seite 258-278 |w (DE-627)NLM012641944 |x 1096-3650 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2021 |g day:15 |g month:01 |g pages:258-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semcancer.2020.04.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2021 |b 15 |c 01 |h 258-278 | ||